SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
558Chuckle. Actually, I'm a great admirer of the BBC...sometimes. Last week tnigel bates-6/17/2005
557I haven't given up on the BBC. Amidst the crackle and spritz of the late niquidditch-6/17/2005
556Hit the BBC news headlines this morning... Which of itself means very little. &nigel bates-6/17/2005
555afr.com First test pass for cancer drug Jun 17 06:40 PA A potential cancer woscaram(o)uche-6/16/2005
554Kosan Initiates Phase I Clinical Trial of Second-Generation Hsp90 Inhibitor KOS-mopgcw-6/6/2005
553Thank You for your timely and informative posts! Greatly appreciated.Bill Tomko-6/3/2005
552[17-AAG Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Humantuck-6/3/2005
551Kosan Presents Data on KOS-953 From Single-Agent and Combination Clinical Trialsscaram(o)uche-6/3/2005
550Color on 17AAG + Bortezomib versus multiple myeloma: Message 21372589 Thanks ttuck-5/31/2005
549[Data on IPI-504 from '05 AACR meeting] >>ANAHEIM, Calif., April 20 /tuck-5/22/2005
548You're referring to Infinity, of which Adams is CSO. Actually that post wastuck-5/22/2005
547There's another competitor in the Boston area. Article was posted somewhere rkrw-5/22/2005
546Meanwhile, over at Conforma, which has a competing molecule targeting HSP 90 tuck-5/22/2005
545[15-amidoerythromycins: new class of antibacterial macrolides] >>J Antibtuck-5/22/2005
544[Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells ovetuck-5/22/2005
543Green tea and HSP90. Message 21337312Icebrg-5/18/2005
542>>ORLANDO, Fla., May 15 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorptuck-5/15/2005
541Kosan Presents Phase I Results on KOS-953 as Multiple Myeloma Treatment at Ameriscaram(o)uche-5/15/2005
540Any thoughts on todays two press releases?Bill Tomko-5/15/2005
539[17AAG + Gleevec didn't prevent regrowth of surviving CML cells] >>Letuck-5/14/2005
538[Efficient production of Erythromycin C; increasing activity of discodermolide] tuck-5/6/2005
537[Preclinical pharmacology of Epo D: dogs better models than rodents] >>Catuck-5/4/2005
536J Clin Oncol. 2005 May 1;23(13):3069-73. Evaluation of Epothilone B Analog in scaram(o)uche-5/1/2005
535>>J Nat Prod. 2005 Apr;68(4):607-10. Production of 8-Demethylgeldanamycituck-4/24/2005
534Cancer Chemother Pharmacol. 2005 Apr 20; [Epub ahead of print] Comparison of scaram(o)uche-4/21/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News